日本語 English

Company Overview

Trade Name
Toyokosei Seiyakusyo Co., Ltd.
Foundation
March 6th, 1948
Capital
10,000,000 yen
Honorary president
Eiichi Tsukiji
Chairman of the board
Fukuyo Tomiya
President and Representative Director
Shoichi Wajima
Head Office
1321 Hino Hino City, Tokyo
Tokyo office
5F Ichiei BLG 2-4-4 Koenjikita Suginami-Ku, Tokyo
Okinawa office
4003 Toyopla, 3-59 Toyosaki Tomigusuku City, Okinawa
Bankers
Tana Shinkin Bank Hino Branch,
Mizuho Bank Hinoekimae Branch
Mitsubishi UFJ Bank Hinoshiyakusyo Branch
Hokkoku Bank Tokyo Branch
Job description
Manufacture and marketing of pharmaceutical products
Export and import and marketing of pharmaceutical products
Manufacture and marketing of Pyro ligneous acid
Manufacture and marketing of refreshing beverages
Manufacture and marketing of supplements
All the businesses related above
Patent
Patent Number: 3411195
Title of Invention: Reactive Oxygen remover

The treatment of the disease caused by reactive oxygen and a prevention or the raw materials


Patent Number: 1617910
Title of Invention: Method for producing platinum or the palladium colloid

The manufacturing method of platinum group colloid by scattering fine particles of platinum / palladium in a solution.

Affiliated organizations
Society of PAPLAL research Director
Society of vitiligo and leukoderma research Member
Antioxidant Unit Supporting Member

Company History

1915
Dr. Noguchi Hideyo who was a student of the Rockefeller Institute for Medical Research came back to Japan only once in his life and then, he entrusted his best friend Saburo Ishizuka (dentist) research and development of Platinum/Palladium colloid (PAPLAL).
Since then, Ishizuka had advanced it with the written instruction from Dr. Noguchi who was living in the United States.
1928
Dr. Noguchi died of yellow fever at Accra in Ghana. (51 years old)
1936
To reward Dr. Noguchi who passed way before it's completion, Ishizuka finally completed PAPLAL with a lot of try-and-error by himself.
It had been 21 years for this only Platinum/Palladium colloidal preparation in the world to be born since he made a promise with Dr. Noguchi.
1938
Toyokosei Seiyakusyo was founded in 1 Naito-cho Shinjuku-Ku, Tokyo to officially manufacture and market PAPLAL.
1940
The trade mark "PAPLAL" was registered.
License of manufacture and marketing of pharmaceutical products was applied to the metropolitan police department at that time and was authorized.
1941
When manufacture and marketing of products were to begin seriously, the pacific war broke out.
Platinum and Palladium that were main raw materials became wartime control products so that it became difficult to obtain them and there was no way but suspending the production with the deterioration of the war.
1948
Toyokosei Seiyakusyo Co., Ltd. was founded.
The first director Saburo Ishizuka took office as the representative director and resumed the production of PAPLAL.
In response to Dr. Noguchi's wish "Medicine for those who are really in need", showy advertisement was refrained and that policy has been continued up to now.
1954
In the Yomiuri Shimbun morning edition (November 28th), it was greatly reported that "PAPLAL originated by Dr. Hideyo Noguchi is a specific medicine for the treatment of patients addicted to Philopon".
1956
"Medicalpractice of the rheumatism-related disease" issued on March 15th, page89 chapter 5 evaluated that "PAPLAL-Platinum/Palladium colloid preparation has greater effect on rheumatic arthritis than the Gold treatment and there is no side effect".
1958
The founder Saburo Ishizuka passed away at the age of 83.
1961
New Pharmaceutical Affairs Law went into effect.
PAPLAL was evaluated as a medicine effective on acute gastroenteritis and chronic gastrointestinal catarrh.
1993
The head office and manufacturing facility moved to Hino City, Tokyo.
The size of colloidal particle of PAPLAL was measured by Dowa Kogyo Co., Ltd.
It was resulted in ultrafine particle (1.5nm). The minuteness of the particle was reassured.
1995
At the department of Polymer Science and Engineering of the Kyoto Institute of Technology, free radical oxygen removal activity was examined with the guidance of Professor Keisuke Makino, Kyoto University.
It was proved to be as much as 100 times of Vitamin C and got attention given from both inside and outside of Japan.
2015
The repigmentation effect of vitiligo vulgaris which is an intractable disease caused by the Platinum・Palladium Nano- colloid is announced by Koichi Shibata of the medical corporation Shibata skin clinic (※). At the same time, Society of vitiligo research was founded. Toyokosei Seiyakusyo had a membership from the beginning and started supporting with the wide range of the study.
(※It appeared in Journal of Pigmentary Disorders 2015.2.5)
2015
Society of PAPLAL research was founded in association with Musashino Pharmaceutical Co., Ltd.
2016
Research of PAPLAL was started by the industry-academia-government collaboration with the help of Hino city and Tokai University Medical department.
2017
The removability of four kinds Reactive Oxygen by the world’s first Platinum・Palladium Nano colloid became clear.
2017
In October, Okinawa Office was set up in Toyogusuku city, Okinawa for the research of the pyroligneous acid from Okinawa and as a circulation base of PAPLAL.
A writing gifted by Dr. Noguchi in 1915

PATIENCE

A writing gifted by Dr. Noguchi in 1915

TOP
Copyright © Toyokosei Seiyakusyo Co., Ltd. All rights Reserved.